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Traumatic Brain Injuries (TBI) are considered one of the leading causes of death and disability 
worldwide. One emerging area of TBI research is the involvement of the endocannabinoid system 
(ECS) in response to brain injury. The ECS is modulated by exogenous cannabinoids such as ∆9-
tetrahydrocannabinol (THC) found in Cannabis sativa. THC is a partial agonist of both 
cannabinoid receptors CB1R and CB2R. CB1R activation is associated with neuroprotective 
effects and contributes to analgesia and anxiolytic effects, whereas CB2R activation reduces 
inflammation. Therefore, the treatment of rats subjected to TBI with THC post-injury may restore 
motor function and improve behavioral profiles of injured rats. In order to assess behavioral and 
physiological changes associated with TBI following a closed head impact injury in a rat model, 
two experiments were performed. Rats were subjected to a closed-head injury impact equivalent 
to a mild/moderate TBI, or sham injury, and subsequently treated with THC or vehicle treatment. 
In the first experiment, 9 rats of both sexes were randomly assigned to: 1) SHAM TBI + Vehicle; 
2) SHAM TBI + 1 mg/kg THC; 3) TBI + Vehicle; or 4) TBI + 1 mg/kg THC. Rats were subjected 
to a number of behavioural measures to assess drug effect, anxiety, working memory, and 
locomotor function following injury. Rats were assessed prior to TBI to establish a baseline, and 
on the above measures for 7 days following TBI.   In the second experiment, 3 rats of both sexes 
were randomly assigned to 1) TBI + Vehicle or 2) TBI + 10mg/kg THC and tested for locomotor 
performance only. According to the data collected, TBI significant decreased male but not female 
locomotor recovery on the rotarod.  Additionally, 1 mg/kg THC administration 1 h post-TBI 
significantly decreased male Sham-TBI, but not female locomotor activity.  In the second 
experiment, visible differences in locomotor recovery were seen between TBI-VEH vs. TBI+THC 
10 mg/kg on day 1-4 following TBI and drug administration, but according to the data collected, 
10 mg/kg THC administration 1 h post-TBI did not significantly impact locomotor recovery post 
injury. THC or TBI did not significantly change other behavioural measures collected. These data 
demonstrate the importance of exploring the therapeutic potential of cannabinoids such as THC 
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Traumatic Brain Injury (TBI) is one of the leading causes of death and disability world-wide (1). 
Brain Injury Canada states that Acquired Brain Injuries, which encompass all-caused brain injuries 
due to traumatic and non-traumatic etiologies, are the leading cause of death among Canadians 
aged 40 and under (2, 3). The Center for Disease Control has confirmed that incidents of TBI 
account for up to 30% of injury-related deaths in the United States (4). According to an 
epidemiological assessment by Fu et al., 2016, in Ontario alone, confirmed cases of TBI during a 
1-year period accounted for up to $1.22 billion in lifetime injury-associated expenses (5). TBIs can 
range from moderate to severe in nature and occur as a result of external mechanical force causing 
alterations in acute and chronic cognitive, physical, or psychosocial function (6). TBIs most 
commonly result from falls, sports-related injuries, car accidents, or physical assaults, and are 
usually accompanied by loss of consciousness, post-traumatic amnesia (PTA), as well as persistent 
cognitive and neurological deficits (7). Injuries ranging from mild to severe are often accompanied 
by persistent memory loss and cognitive deficits lasting for months to years post-injury (8). Men 
are twice as likely as their female counterparts to suffer a TBI, with the largest number of TBIs 
occurring in children under the age of 4 or adults over the age of 85 (5). Despite a lack of 
epidemiological investigation, a review by Langlois in 2006 estimated that globally, sports related 
TBI were responsible for approximately 1.6 to 3.8 million injuries per year (9). More recently, 
recognition within Canadian amateur and professional national sport communities has increased, 
resulting in a surge of TBI incidences being reported, but data is still limited (10).  The 5th 
International Conference on Concussion in Sport (11, 12) released updated clinical assessment 
tools and return-to-sport guidelines to address lasting gaps in diagnosis and rehabilitation; yet 
persistent social stigma, the pressure to “return to normal”, and a lack of available pharmacological 
treatments for TBI leave many at risk (13).  Depending on the injury’s severity, cognitive and 
neurological deficits can persist long-term, causing a lifetime paradigm shift for the persons injured 
as well as for their loved ones.  
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One emerging area of TBI research is the involvement of the endocannabinoid system (ECS) 
following brain injury. The ECS is a system within the human body that is responsible for 
numerous physiological functions such as temperature, nociception, and locomotion, as well as 
higher level cognitive and behavioural functions (14, 15). As awareness surrounding post-traumatic 
complications and return-to-sports activities increases, the need for research examining this 
intricate relationship is apparent. This is in part because endogenous cannabinoids may possess 
neuroprotective and inflammatory mediating properties (16). These endocannabinoids, which are 
produced by neurons and other cells in the body, modulate pain (17), anxiety (18), and general 
neurotransmitter release through the activation of the type 1 cannabinoid receptor (CB1R) and 
inflammation (19) through the type 2 cannabinoid receptor (CB2R). CB1R is the most abundant G 
protein-coupled receptor (GPCR) in the central nervous system and is found in areas of the brain 
linked with motor learning, memory, reward pathways, and higher cognitive processing (20). 
Because of these known modulatory roles, the ECS and cannabinoids may play a role in the 
treatment of TBI. However, to date there has been a lack of research into the effects of TBI on the 
ECS, pre-clinical or otherwise.  
 
As the ECS is the system on which cannabinoids from Cannabis sativa (cannabis) and its 
derivatives act, the use of cannabis in TBI treatment also deserves investigation. Indeed, ∆9-
tetrahydrocannabinol (THC), the intoxicating constituent of cannabis, exerts its effects by 
activating both CB1R and CB2R (15). Up until its recent legalization, research into cannabis and 
its derivitives has been limited. This has left a large gap in our overall clinical understanding of 
cannabis, cannabinoids, and their potential theraputic effects. The lack of therapeutics available for 
TBI, in conjunction with recent legalization and the therapeutic potential of cannabis, opens the 
door to undiscovered drug therapies for this debilitating condition.  
 
Much like available data on sports-related TBI, little is known about the prevalence and patterns 
of cannabis use in sports (21).  Despite THC being banned according to the World Anti-Doping 
Agency (WADA), cannabis is the 2nd most widely used recreational drug behind alcohol among 
athletes, and its use is associated with higher-risk sports (22). Numerous anecdotal self-reports 
exist of contact sport players using cannabis for post-game analgesia, as well reported use to 
decrease pre-competition anxiety and increase focus, yet available research is exceptionally limited 
(23). Therefore, research in this area is critical regardless of positive or negative results, as our data 
will add to the growing body of knowledge on the topic for policy, education, and health care 
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applications affecting TBI and cannabis use in sport and overall health from a harm reduction 
perspective.  
 
The goal of the research described here is to explore how the ECS changes in an animal model of 
TBI, and to measure whether or not the ECS can be targeted with THC to restore motor function 




1.2. TBI Pathophysiology  
 
The term TBI is an umbrella term used to define a complex neurological event, induced by 
biomechanical forces resulting in mild to serious downstream physiological, behavioural, and 
cognitive consequences. TBI is a multifaceted injury, characterized by numerous 
pathophysiological changes within the brain that have been triggered by an original structural 
injury, known as the primary injury (24). This mechanical primary injury causes immediate 
contusions to the injured area, diffuse shearing of axons and blood vessels, damage to glial cells, 
cytoskeletal disruptions, as well as localized hemorrhaging (25-29). TBI severity in its early stages 
is assessed via the Glasgow Coma Scale (GCS), the current gold standard clinical assessment of 
TBIs, which grades duration of loss of consciousness and duration of acute memory loss on a scale 
of 3-15, where high numbers are associated with better patient outcomes (30-31).  The primary 
injury is untreatable but can be prevented by the introduction of safety measures and personal 
protective equipment.  
 
The secondary injury cascade involves widespread cellular, molecular, and biochemical changes 
that develop following the primary injury (32-34). These pathophysiological mechanisms are 
characterized by ion, neurotransmitter, mitochondrial, and cerebrovascular dysregulation leading 
to eventual cell death and resulting chronic impairments demonstrated in figure 1-1 (27, 35). The 
secondary injury evolves from minutes to years post-injury due to neuronal hyperexcitability, glial 
cell dysregulation, lipid degradation, cerebral edema, nitric oxide (NO) synthesis, and eventual 
widespread neuroinflammation, ultimately resulting in brain cell death, tissue damage, and atrophy 
and the potential accumulation of protein such as amyloid precursor and tau protein (26, 36-38). 
The severity of the second injury cascade is difficult to predict due to the heterogeneity of injury 
morphology and magnitude. This paired with the omnipresent demystification of the intricate 
neurometabolic cascade is perhaps the reason why modern medicine has failed to provide reliable 
pharmaceutical intervention.  
 
Scientific investigation has focused on the various known downstream effects of the secondary 
injury cascade as potential therapeutic targets to decrease functional deficits associated with the 
primary injury. One specific area of focus has been the widespread CNS excitotoxicity immediately 
following the onset of adverse biomechanical forces to the cerebrum. Regardless of injury severity, 
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mechanoporation of axons, caused by shearing forces exerted on axons, leads to adverse molecular 
perforations of their lipid membrane (32, 39-40). It is suggested that these mechanoporations allow 
ion leakage, resulting in mass depolarization of voltage- and ligand-gated ion channels, ultimately 
leading to wholesale glutamate and aspartate release and Ca+2 influx in an unregulated and 
damaging fashion (41-43). The widespread CNS excitation causes largescale influx of Ca2+ which 
is hurriedly sequestered into mitochondria, leading to mitochondrial dysfunction and lasting 
disruptions of energy production (44). Mitochondrial dysfunction is further perpetuated by injury 
driven generation of damaging free radicals such as nitrogen and oxygen species (RONS) like NO, 
synthesized en-masse as part of the second injury cascade (45). When left unchecked, this spread 
of synaptic depression, cellular Ca2+ imbalances, energy deficits, and RONS accumulation 
contributes to post-injury complications such as seizures, critical dendritic edema and eventual cell 
death (46). These cellular cascades trigger molecular signals driving downstream immune 
activation and subsequent cytokine and chemokine release, pushing the initial robust post-
traumatic neuroinflammatory response that lasts for weeks to years following injury (47). 
According to the review of Simon et al. (2017) this inevitable and critical immune cascade resulting 
in persistent neuroinflammation is increasingly seen as a necessary, but potentially harmful, 
biological coping mechanism, and an important focal point for pharmaceutical interventions (33).  
 
Another area that has gained interest in brain injury research is the impact of changes incurred by 
primary injury on cerebrovascular architecture and regulation. The brain is supported by highly 
sensitive vascular regulatory mechanisms, the most influential of which in TBI is the blood brain 
barrier (BBB) a functional and metabolic “barrier” between the brain and the body’s circulation 
characterized by tight junctions between endothelial cells in the surrounding cerebral 
microvasculature (48, 49). When disrupted during primary injury and further compromised during 
secondary injury, a lapse in BBB function acts much like the opening of a cerebro-vascular flood 
gate in its cause and perpetuation of severe edema (49-51). This mass perfusion overwhelms 
vascular autoregulatory mechanisms and causes dramatic shifts in cerebral blood pressure and 
oxygenation (52, 53). The dysregulation of these protective mechanisms has been shown to persist 
for days to weeks post injury (54), contribute to acute risk of reinjury (55) and lasting functional 
impairments (56).  
 
These compounding dysregulated conditions reflect poorly on neuronal connectivity, and 
commonly produce lasting behavioural, cognitive and neuromotor symptoms (57).  One potential 
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means of therapeutic intervention for the treatment of the secondary cascade associated with TBI 
is the use of THC.  THC is a compound of interest in TBI research because of its CB1R and CB2R-
mediated potential to quell glutamate excitotoxicity, the generation of free radicals and lipid 
peroxidation, and to mitigate apoptosis, perturbations of cellular calcium homeostasis, vascular 
dysregulation, and associated cognitive and behavioural deficits, all of which are avenues of focus 







Figure 1-1: Downstream Primary and Secondary Injury Cascades. Summary of secondary 
injury mechanisms accompanying initial primary injury, responsible for long term impairments. 




1.3 Mild to Moderate Traumatic Brain Injury (mTBI)  
 
According to the most recent consensus statement on mTBI in sport (12), a mild to moderate TBI 
is defined as a head injury induced by external biomechanical forces incurred by an insult to the 
head, face, or neck that are frequently accompanied by rapid acceleration and deceleration of the 
brain within the skull (58). mTBIs are often accompanied by acute impairment of neurological 
function, neuropathological changes, a GCS measure ≤9, disruptions in normal cognitive function 
that may include loss of consciousness and PTA, as defined previously. Mild TBIs are 
characterized by functional disturbances rather than overt structural abnormality, whereas 
structural abnormalities and non-operative lesions may be visible via neuroimaging in moderate 
TBI (12, 59).  
 
mTBIs have gained international publicity due to the increased rates of Chronic Traumatic 
Encephalopathy (CTE), a neurodegenerative disease characterized by chronic behavioural and 
cognitive changes attributed to cerebral atrophy and neuronal death caused by accumulation of 
phosphorylated tau and amyloid-β (Aβ) proteins presenting as neurofibrillary and astrocytic tangles 
and TDP-43 protein pathologies following injury (60-63). CTE has been diagnosed post-mortem 
in boxers, hockey players, and football players (64-66). mTBI has gained further recognition in 
Canadian sports communities following the implementation of Rowan’s Law in Ontario. Rowan’s 
Law commemorates a young local female rugby player who died suddenly from Second Impact 
Syndrome (SIS), a syndrome resulting from the increased metabolic vulnerability of a still-
symptomatic brain, sensitive to reinjury, which leads to loss of autoregulatory mechanisms and 
subsequent lethal physiological cascade from a sublethal second impact (55, 67).  
 
mTBI are shown to have acute and lasting chronic impacts. Upwards of 75% of TBIs reported are 
considered mild to moderate in nature and are diagnosed according to the presence of clinical 
somatic, cognitive, and emotional symptoms (12, 68). Although mTBIs constitute the most 
common phenotypes of TBI, mTBIs remain the most underreported and misunderstood type of TBI 
in both human and animal models (69,70). Despite being illustrated mainly by molecular cascades 
that rectify within a matter of days, these examples of life-threating chronic and acute pathologies 
highlight the importance of translational research quantifying systems and targets associated with 
acute secondary injury cascades following the primary mTBI.  
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1.4 Cognitive and Behavioural Implications of TBI 
 
TBI is a complex pathology due to the overlapping nature of persistent symptoms. The complex 
onset of neurocognitive, behavioural, and motor changes resulting from the intricate 
neurobiological second injury cascade have a profound long-term impact on the relationships, 
mental health, and independence of severely injured individuals (71). Acutely, in the first hours to 
days following the injury, all but the mildest TBIs are associated with short term memory gaps 
immediately following injury, referred to as PTA. PTA manifests as temporary periods of 
confusion and amnesia accompanied by agitation; disturbances in sleep/wake patterns, arousal, and 
general disorientation (72). Seventy percent of patients suffering from mTBI are expected to make 
a full recovery within 3-6 months post-injury (12). However, in a study of 375 emergency room 
confirmed mTBI cases, over 82% of those assessed were plagued by persistent neurophysiological 
symptoms 1 year post-injury (73). These persistent symptoms (months to years) are known as Post-
Concussion Symptoms (PCS), and are characterized by headaches, confusion, sleep difficulties, 
nausea, decreased cognitive capacity and memory, dizziness, and gait changes (8, 29). Persistent 
symptoms are omnipresent in moderate to severe TBI, where basic functional recovery stretches 
for 3-12 months. For this reason, data in more severe cases of TBI typically focus on lifelong 
impact of injury, where upwards of 65% of patients report persistent cognitive, psychiatric, and 
behavioral dysfunction for years following TBI (74).  
 
Symptoms of both short-term behavioural and cognitive impairments, as well as TBI-induced 
neurodegeneration, largely result from alterations in executive function due to direct injury to the 
frontal lobes, to changes in system connectivity resulting from diffuse axonal damage, or to a 
combination of the 2 (75). According to an analysis of lateral impact versus dorsal impact methods 
for mTBI by Mychasiuk et al. 2016, despite a similar injury severity and acute neurological 
symptoms, the location and rotation of impact resulted in significantly different emotional and 
cognitive function between groups (76). These results demonstrate that injuries implicating 
different white matter tracks may contribute to variation in lasting cognitive deficits following 
injury.  It is of note that chronic neuromotor dysfunction is a generally a function of injury severity 
and is therefore more prominent and long-lasting in severe TBI, which is not the current focus of 
this research. Typical behavioural changes associated with mild to severe TBI are characterized by 
decreases in attention and concentration, decreased processing speed, increased impulsivity, 
irritability and aggression, variable judgment, and changes in memory acquisition and mood (77, 
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78). Both acute and chronic symptoms are aggravated in the presence of co-morbidities, such as 
pre-existing diagnosed or undiagnosed psychiatric conditions, migraines, history of previous TBI, 
as well as concomitant injuries sustained in conjunction with the TBI (8).  Age and sex can also 
impact the development of acute and chronic symptoms (8).  Research indicates that various 
aspects of acute injury pathophysiology play a role in the manifestation of cognitive and 
behavioural changes. More and more, acute (less than 3 months) and persistent (over 6 months) 
cognitive, behavioural, and neuromotor complications have been associated with an inflammation-
induced neurodegenerative sequela (33,79). Of note, Shultz et al. demonstrated in a 2012 study that 
as much as 1 sub-concussive injury increases markers of neuro-inflammation without remarkable 
behavioural dysregulation (80). This suggests that a less-than-clinical injury can easily contribute 
to neurodegenerative damage. In another rodent model of mTBI, cognitive and behavioural 
discrepancies were ameliorated 7-days post injury by interrupting synthesis of inflammatory 
cytokines such as TNFa (81), further demonstrating the interplay between inflammation and 
behaviour changes. The diagnosis of TBI-associated neurodegenerative pathologies, such as 
Alzheimer’s disease and CTE, are frequently diagnosed post-mortem in individuals with a history 
of mild repetitive neurotrauma such as uncontrolled epilepsy, physical abuse, and repeat mTBI in 
sport (61, 82), as well as after a single moderate to severe TBI (83). Importantly, a review by 
McInnes et al. (2017) examining short and long-term cognitive function in individuals with a single 
mTBI determined that 55% of study participants assessed experienced cognitive impairments 
lasting upwards of 1-year post-injury, which further highlights the indiscriminatory impact of a 
single mTBI on overall health (84). 
 
Due to the unpredictability of injury severity and underlying comorbidities, the extent of cognitive 
and behavioral deficits present in the early stages of recovery are difficult to predict and encompass 
a poorly researched area of traumatic brain injury. Due to the associated changes in behavior, 
cognitive function, and mood seen in TBI, animal models serve as a functional way to assess 
biomechanical impact on behavioral outcomes, such as anxiety- and depression-like behaviour, 
sociability, motor function, and memory (85). Using targeted behavioural analysis paired with 
appropriate animal models replicating human injury mechanisms is an important way to further 
elucidate complex lasting impacts of the spectrum of TBIs.  
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1.5 Animal Models of TBI  
 
Animal models serve as a bridge to examine TBI severity and complexity by creating various 
models of injury mechanisms to explore resulting pathophysiology and behavioural changes. 
Despite our best efforts, not all animal models of TBI remain equal. Notably, there remains a 
disconnect between injury severity in humans and animals because the common means of 
quantifying injury severity in humans, such as injury-associated somatic, cognitive, and emotional 
symptoms are unavailable in rodent models. Furthermore, use of anesthetics and analgesics post-
injury can alter symptom manifestation, leaving judgment of severity largely to physiology, 
histopathology, and to measures of rodent behaviour, which are themselves imperfect.  According 
to a review by Bodnar et al. (2019), the most commonly used models of TBI are the focal, diffuse, 
and mixed model injuries; and choice of model largely depends on what is being examined (86). 
Focal injuries, named from the latin word, focus, indicate an injury resulting from direct impact to 
a specific region of the skull causing potential fracture and significant contusions and bleeding 
(87). A focal injury is frequently performed on an open head, meaning the animal undergoes 
surgery to expose the skull or dura to which a weight is dropped or a pressurized impact, also 
known as a Controlled Cortical Impact (CCI) is then administered to the focalized site of injury. A 
focalized injury may be administered on a fixed head or unfixed and is most commonly used to 
explore the injury pathology to further understand the secondary mechanism of injury (88).   
 
Diffuse injuries on the other hand can occur without any direct contact to the head, and are used to 
emulate the shearing forces due to acceleration and deceleration of the brain commonly responsible 
for behavioural phenotypes of mTBI (89). The injury incurred by this type of mechanism is highly 
variable, and therefore mimics some of the variability seen in human motor vehicle accidents, 
sports injuries, and blast injuries (90). In pre-clinical research, due to a lack of homogeneity 
between diffuse injury mechanisms, diffuse injuries are best emulated with non-penetrating blast 
wave models, such as fluid percussion, emulating injuries emerging from military engagement, and 
therefore require specialized equipment (89).  
 
Most commonly, mTBI etiology results from a combination of both focal and diffuse injury 
mechanisms, defined in pre-clinical research as a mixed-model injury. The mixed model injury is 
administered via variations of the weight drop model as well as CCI where animals are placed on 
foam or allowed to rotate or free fall following the weight drop or CCI (89, 76). Helmet-like devices 
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are occasionally used to increase or decrease the injury severity and modify the ratio of focal to 
diffuse injury type (90).  
 
Regarding injury severity, a significant amount of the research available on rodent models of TBI 
has been centered around the extremes of the injury spectrum (severe and mild), leaving to question 
the investigation of moderate TBI. I highlight the variation because according to a 2019 systematic 
review of closed head mild TBI by Bodnar et al. (86), the largest proportion of rodent models of 
mild TBI used was the weight drop, with the majority of these mimicking the classic Marmarou et 
al. (1994) model which uses a 450-500 g weight dropped from a 1-2 m height (91). The Marmarou 
method cites intubation as part of the procedure or else the death toll in rats subjected to the injury 
@ 50% (91), symptoms rarely seen in clinical mTBI.  Upon closer examination of other adapted 
mTBI weight drop models featured in this review, weight drops as low as 10 g and as high as 1,600 
g in rats with or without the use of protective head gear were considered “mild” (86). This disparity 
in weight drop models only highlights the need for widespread consensus on models of sub-
concussive, mild to severe, and repeat injury between weight drop and other more complex mixed 
method injury models. Although I have highlighted gaps in research pertaining to symmetry 
between injury methods, this is once again not the goal of this project; yet still more critical when 
actively contributing to the growing body of knowledge on this topic.  
 
For this reason, consensus and universal use of functional and uniform mixed models of brain 
injury that are easily replicable and encompass the diffuse axonal injuries present in rotational and 
acceleration injuries akin to sports and motor vehicle collisions, in addition to focal injury 
characteristics of direct head trauma, are important when examining behavioural sequelae 






1.6 The Endocannabinoid System 
 
Research into the ECS entered mainstream biomedical research in 1964 with the discovery of THC, 
and has since gained popularity within the research community at an exponential rate despite its 
longstanding controversial nature. As previously noted, the ECS is a system within the human body 
that regulates numerous critical physiological and behavioural functions. More specifically, the 
ECS actively participates in potentiating synaptic plasticity and neurogenesis and when 
dysregulated, it has been associated with numerous neurodegenerative and psychiatric conditions 
such as Huntington’s disease, Parkinson’s disease, and mood disorders such as schizophrenia (92, 
103).  The biological importance of the ECS is further amplified by its presence and modulating 
capacity in all vertebrates (93). Much like other commonly known systems, the ECS consists of 
endogenous ligands, and anabolic and catabolic ligand-specific enzymes and receptors.   
 
The two main receptors within the ECS are CB1R and the CB2R (94). These 2 receptors are 
GPCRs, and, like other GPCRs, are composed of 7 transmembrane a-helices and play a critical 
role in initiating downstream signalling of hormones and neurotransmitters (95).  They are 
considered the main receptors of the ECS and are both activated by endogenous and exogenous 
cannabinoids.  
 
CB1R is one of the most common GPCRs within the CNS (96) and is largely expressed in the CNS, 
on neurons, with its highest concentrations in the cerebral cortex, striatum, hippocampus, and 
cerebellum (15, 97). These are all areas that are highly implicated in TBI-related mood and motor 
deficits. The activity of CB1R depends on the cell type (excitatory or inhibitory), as well as the 
location on the cell.  Importantly, CB1R participates in the activation and deactivation of numerous 
critical cell signalling pathways associated with cellular communication, proliferation, and 
apoptosis such as MAP kinase phosphorylation, cAMP inhibition, Ca2+ channel inhibition, and 
inflammatory pathways via NO and arachidonic acid (AA) (15, 98, 99). Its activation is considered 
neuroprotective because it dynamically depresses glutamatergic excitotoxicity (100), which in turn 
slows the production of RONS and associated cell death (71).  
 
CB2Rs, on the other hand, are found primarily in the periphery located on virtually all types of 
immune cells, in both the innate and adaptive immune system (macrophages, monocytes, and T 
and B cells), as well as on microglia in the CNS, and to a lesser degree on neurons (101, 102). 
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Importantly, CB2R activity is upregulated in the presence of inflammation and chronic 
neurological diseases (15, 101, 13). According to a review of CB2R pharmacology, conducted by 
Turcotte et al. (2016), agonists of CB2R consistently produce anti-inflammatory downstream 
signalling, mainly through the modulation of leukocytes (98). In a TBI-specific example of CB2R 
mediated anti-inflammatory effects, Amenta et al. (2014) (104) demonstrated that both CB2R 
knockout mice and those treated with CB2R antagonist exhibited significantly higher levels of 
TNFa, inducible NO synthase (iNOS), and intracellular adhesion molecules-1 (ICAM-1). iNOS is 
an enzyme present only during inflammatory episodes associated with free radical accumulation 
during TBI, and ICAM-1 is a protein responsible for enhanced endothelial permeability enabling 
leucocyte migration across the BBB resulting in subsequent allocation of edema into the brain and 
signaled by TNF-a (105). Similarly, when fetal astrocytes were treated with WIN55,212-2, a 
synthetic CB1R and CB2R agonist, iNOS and associated NO production was interrupted in 
addition to the inhibition of TNF-a and a number of inflammatory chemokines (106). The above 
research indicates that both CB1R and CB2R possess unique and intimate modulatory roles in the 
maintenance of homeostatic control in the face of inflammatory insult.   
 
Of the 15 known endogenous compounds synthesized on demand to activate the ECS, anandamide 
(AEA) and 2-arachidonoylglycerol (2-AG) are the most abundant and well-studied (107). Both 
AEA and 2-AG, in addition to a few lesser known endocannbionids, (14) are known to work on 
CB1R and CB2R, in addition to other non-cannabinoid-based receptors such as non-cannabinoid 
GPCRs, transient receptor potential channels (TRP), ionotropic receptors, and peroxisome 
proliferator activated receptors (PPAR) (14). The primary pharmacological effects of the 
cannabinoids are thought to be on the GPCRs CB1R and CB2R.  
 
At homeostasis in the CNS, 2-AG is found in higher concentrations than AEA, and acts as a full 
agonist at both CB1R and CB2R (108). AEA, on the other hand, acts as a partial agonist at CB1R 
and to a lesser extent at CB2R (109). AEA anabolism is complex but it is largely synthesized by 
N-arachidonoyl phosphatidyl ethanolamine-specific phospholipase D (NAPE-PLD) (110), and 
catabolized by fatty acid amide hydrolase (FAAH) (111). 2-AG is synthesized from arachidonoyl-
containing phosphatidyl inositol bis-phosphate (PIP2) by diacylglycerol lipase (DAGL), and is 
catabolized by enzymes monoacylglycerol lipase (MAGL) and ABHD6/12 (112, 113). Notably, 2-
AG acts as a precursor to arachidonic acid (AA), which is important for prostaglandin synthesis 
 15 
and thus critical for inflammatory pathways (COX-1 and COX-2) (114). CB1R resides on the pre-
synaptic membrane of neurons, and its endogenous ligands travel in a retrograde direction from 
post-synaptic membrane to pre-synaptic membrane to suppress pre-synaptic neurotransmitter 
release in a stimulus-response-dependent fashion (Figure 1-2)(71). Both of these endocannabinoids 
are manufactured on demand according to intracellular levels of Ca2+ (115), which is indicative of 
their ability to modulate neuronal activity. 
 
Another important part of the ECS and its function are the exogenous cannabinoids that interact 
with the system. Over 120 unique phytocannabinoids have been identified from the Cannabis 
sativa plant (116), with the main 2 constituents being THC and cannabidiol (CBD). THC acts as 
the main psychoactive component of Cannabis, and much like AEA, acts as partial agonist at the 
CB1R and CB2R receptors. It therefore possesses both potential neuroprotective activity at CB1R, 
and the ability to subsequently mediate excitatory and inhibitory neurotransmissions (117) and 
anti-inflammatory activity at CB2R by regulating inflammatory cytokine release and movement of 
immune cells in the CNS (103, 118).  CBD, on the other hand, is less well understood in its action 
and does not possess psychoactive properties. CBD has been shown to act as a possible antagonist 
or negative allosteric modulator at CB1R, and as a partial agonist at CB2R (119-121). Evidence 
also suggests that the bulk of CBD’s activity is seen at non-cannabinoid receptors (98), further 
contributing to the complexity of the ECS. The ubiquity and importance that the ECS, its 
endogenous ligands, exogenous cannabinoids, and non-cannabinoid-based receptors makes this 













Figure 1-2. Snapshot of Retrograde Signaling of the CB1R and CB2R. A visualization of 
endocannabinoid action at CB1R and CB2R in microglia and neurons. Figure created by author, 
using information from (207).  
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1.7 The Endocannabinoid System In TBI 
 
The complex pathophysiology of TBI and the overlap of the ECS present an interesting intersection 
in the exploration of pharmacological interventions, but until this point, all investigation into the 
ECS and TBI has remained pre-clinical in nature. It is established that in a healthy state, 2-AG is 
present in the CNS in 2 to 3 times higher concentrations than AEA (122) and in a TBI state of 
glutamatergic excitotoxicity, CNS concentrations of both AEA (123) and 2-AG (124-126) increase 
over the following hours to days post-injury. This suggests that the ECS acts as a self-regulatory 
mechanism to reduce Ca2+ flux and decrease accumulation of RONS (127, 128). Research into the 
inhibition of FAAH, MAGL, and ABHD6 to increase endogenous AEA and 2-AG has been linked 
to decreased inflammatory cytokine production, microglial activation, BBB breakdown, and 
improvements in behavioural measures (Figure 1-3) (123, 128-130).  Administration of other lesser 
known endocannabinoids such as, N-arachidonoyl-L-serine (131), palmitoylethanolamide (132) 
promote neurogenesis and vascular recovery, respectively, post TBI.  Early research examining the 
neuroprotective properties of the exogenous cannabinoid THC at 1 mg/kg i.p. and AEA transport 
inhibitor AM404 at 2 mg/kg i.p. administered 5 min after a carotid occlusion ischemic injury 
protected gerbils from any damaging effects of the injury, according to behavioural and EEG 
measures (133).  A study by Belardo et al. (2019), 1 of the few publications available exploring the 
therapeutic action of phytocannabininoids in TBI, found that CBD (30 µL with 10% CBD), 
administered orally, partially recovered behavioural, neurological and biochemical deficit post 
mTBI in mice, but failed to indicate glutamate levels (134). Another study by Amenta et al. (2012) 
demonstrated that the treatment of murine models of TBI with the CB2R agonist O-1966 decreased 
BBB disruption and neuronal damage, and improved behaviour when compared to vehicle control 
(135). A 2020 publication by Bhatt et al. indicated that the repeat administration of 1.25 mg/kg i.p. 
THC after repeated mild TBI via a 50 g lateral impact device led to partially recovered anxiety- 
and depression-like measures and deficits in working memory, but did not when THC was 
administered pre-injury (136). It is clear that more research is necessary despite the pre-clinical 
research available exploring the therapeutic possibilities of endocannabinoids, synthetic 
cannabinoids, and inhibition of catabolic enzymes, as well as the limited research available to 
indicate the efficacy of exogenous plant cannabinoids – such as the CB1R and CB2R partial agonist 
THC – as a therapeutic intervention (71).  
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Another issue for consideration is the ever-growing presence of anecdotal evidence touted in the 
media for the therapeutic effects of phytocannabinoids. Advertisers are appealing to professional 
and recreational athletes alike for the use of cannabis and cannabinioids for anything from sleep 
enhancement, to post-training recovery, to supposed performance enhancement, despite an 
astounding lack of data. One of the few limited sources of information on potential clinical 
implications of cannabinoids is indicated in a 3-year retrospective study at the UCLA medical 
center by Nguyen et al. (2014), which explores the correlation between injury mortality and THC 
concentrations in urine. They found that in TBI patients, those who screened positively on urine 
toxicology for THC had a decreased mortality in comparison to patients who screened negatively 
(137). Although there is a lack of research on the topic, this is an area of science that requires 








Figure 1-3. Cannabinoids in TBI. Summary of cellular and molecular pathways by which 
cannabinoids exhibit pharmacological therapeutic potential in TBI induced secondary injury 







According to previous research, TBI treatments have been split into neuroprotective strategies, 
which are aimed at decreasing the secondary injury and the associated neuronal cell death; or 
neurorestorative strategies, which focus on neurovascular remodeling, as well as neurogenesis, 
oligodendrogenesis, and dendrite and axon extension (13). Recent preclinical research indicates 
that the ECS and exogenous cannabinoids possess numerous promising modulatory pathways to 
intervening in the secondary injury cascade of TBI (138, 71).  
 
Past research has shown that following TBI: (i) the endocannabinoids AEA and 2-AG are 
significantly upregulated (139, 124); (ii) levels of the excitatory neurotransmitter glutamate 
increase whereas levels of the inhibitory neurotransmitter GABA decrease (140); (iii) CB1R and 
CB2R are upregulated (141, 142); and (iv) inflammatory cytokine production increases (27). Prior 
research in rodent models of TBI has shown a significant decrease in exercise capacity, motor 
coordination, stamina, grip strength, balance, working memory, and spatial learning (143); as well 
as increased anxiety compared to healthy controls (144). THC is a partial agonist of CB1R and 
CB2R. Activation of these receptors via THC reduces glutamate release, cytokine production, 
spasticity, and anxiety (16). Based on our pre-existing understanding of the ECS, TBI, and THC, 
the hypothesis of this study is that treatment of rats subjected to TBI with THC post-injury 




Chapter 2 Materials & Methods 
 
2.1. Animal Care 
 
Sixty-three Sprague-Dawley rats of both sexes, approximately 8-12 weeks old at the time of 
experiment, were obtained from Charles Rivers Laboratories Inc. (Senneville, QC, Canada). Rats 
were chosen as an adequate translational model because the human and rat CB1R and CB2R 
respectively hold 97% and 93% amino acid congruency (15). Rats were housed 2 per cage, in same-
sex pairs with appropriate environmental enrichment, bedding materials, and ad libitum access to 
food and water. Animals were maintained on a 12 h light and dark cycle established by the Lab 
Animal Service Unit (LASU) at the University of Saskatchewan. Following the completion of in 
vivo data collection, all rats were euthanized by overdose of isofluorane (5%) followed by 
decapitation. Whole brains were collected and stored at -80 C.  
 
All procedures and protocols described below were performed with approval from the of University 
Animal Care Committee (UACC) and Scientific Merit Review Committee for Animal-Based 
Research (SMRCABR) and are in keeping with the guidelines of the Canadian Council on Animal 
Care (CCAC) and the ARRIVE guidelines. 
 
2.1.1 Terminal endpoints 
 
During housing and interventions described above, any animal was removed from the experiment 
if they qualified for any 3 of the possible terminal endpoints. These terminal endpoints include 
animals who appeared pre-moribund; experienced weight loss exceeding 15%; showed a decrease 
in body temperature greater than 6°C; or had any ulceration, bleeding, self-mutilation, skull 
fractures, or severe and prolonged lethargy or stress in addition to any severe reactions such as 
unanticipated seizure activity, depression, or pre-comatose state. Over the course of this project, 2 





2.2 TBI Protocol 
 
Based on extensive analysis of previous research, in accordance with results from Bodnar et al. 
2019, as well as previous research by Mychasiuk et al. 2014, a modified weight drop model with 
additional PPE was chosen for this experiment due to its ability to produce, at low cost, a reliable 
and reproducible injury, producing similar behavioural deficits characterized by other more 
complex pre-clinical models (76, 89, 90).  
 
Prior to TBI, rats were habituated to the procedure room for 15 min. Rats were anesthetized (3% 
Isofluorane) and subjected to a modified closed head impact to simulate motor vehicle and sports 
induced TBI. Isofluorane 3% was the approved anesthetic for use by the animal care committee 
and is frequently used in close head TBI models (145). This TBI model has been adapted from 
Mychasiuk et al. (2014), and Qin et al. (2018), whose injury models marry focal and diffuse injury 
patterns associated with TBI (90, 146, 147), thereby replicating a functional model where contact 
forces, inertia forces and rotational acceleration are combined (24) (Figure 2-1).  
 
Set up of the TBI apparatus required a metal guide tube (15 mm inner diameter x 1.25 m height), 
a ring stand, a clamp, a weight with metal ring at the top, parachute cord (2 mm), a metal key ring, 
and a metal pin. A weight, 300 g total (comprised of 1 detachable 100 g weight and 4 detachable 
50 g segments with a total length at 248.5 mm long) was designed and fabricated by the 
Engineering Shops, University of Saskatchewan. A hole was drilled into the metal guide tube using 
a drill press, 248.5 mm from the top of the guide tube, where a metal holding pin was inserted to 
suspend the 300 g weight. One and one-half metre of parachute cord was attached to the metal loop 
of the weight and the metal key ring was attached to the end of the cord. In order to produce the 
accelerative and rotational forces that often accompany sports- and vehicular-related TBI, rats were 
suspended on a sheet of aluminum foil that had been taped to the top of a clear plastic box (38 x 
25 x 35 cm3) positioned below the TBI apparatus and scored horizontally four times with a razor. 
Placed within the box was a foam collection sponge (38 x 25 x 10 cm3). According to previous 
models, the use of aluminum foil to suspend the rat allows for it to rotate 180 degrees following 
the impact of the weight being dropped, producing a more functional mechanism of injury.  
 
In order to elicit a TBI, 1 rat at a time was placed in a sealed transparent box and anesthetized with 
1.5 L/min oxygen and isoflurane (3%) until their pedal reflex was no longer responsive. Following 
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anesthesia, the rat was briefly transferred to a head cone and heating pad where the dorsal part of 
their cranium was shaved, and a stainless-steel disc (“helmet”) (10 mm x 2 mm) was fixed with 
dental cement on the sagittal mid-line between the inter- aural line and bregma to indicate the 
impact site and protect the skull demonstrated in Figure 2-2. Once the helmet was securely 
fastened, the rat was quickly transferred to the aluminum foil, and placed in the prone position with 
their helmet positioned below the guide tube. At this point, the animals ceased to receive anesthetic. 
In total, anesthetic duration was < 15 min for all animals except for one (< 30 min) due to a fire 
alarm. The weight was then dropped to produce a TBI. Following impact, the rat was transported 
to a recovery cage placed on top of a heating pad with a pulse oximeter, in order to monitor heart 
rate and blood oxygen content until the rat regained consciousness. Heart rate and blood oxygen 
were monitored directly before and after injury (Appendices 1-3) and the day before the procedure 





Figure 2-1. Modified Weight Drop Model. Graphical representation of mixed injury model used 
to emulate a combination of diffuse and focal injuries characteristics commonly seen in sports-
related and motor vehicle accidents. Figure created by author in reference to model adapted from 







Figure 2-2. Protective Stainless-Steel Disc. A helmet-like structure used to diffuse the 300 g 
impact to create an injury model more closely resembling a moderate TBI. Figure created by 









Figure 2-3. Experimental Timeline. This timeline illustrates both baseline measure collections 
(day -4 to -1), Injury and THC Injection date (Day 0), as well as the following 7 days of post-injury 
data collection (day 1-7).  
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2.3 The Rotarod  
 
The rotarod is a test used to quantify vestibulo-motor function in rats following TBI by testing grip 
strength, coordination, and balance of the animal. The Rotarod (ROTO-ROD, Series 8 IITC Life 
Science) is a motorized cylindrical rod that rotates at varying speeds, as demonstrated in Figure 
2-4. Rats were pre-trained on the rotarod for four days prior to TBI (Day -4 to -1) and tested on 
days 0, 1, 2, 3, 6 and 7 following the TBI on day 0 (see Figure 2-3). Animals were habituated to 
the treatment room and instrument for 3 days prior to data collection. Rats were allowed to 
habituate in a neighbouring room for a minimum of 10 min, and to habituate in the rotarod room 
for 5 min pre-rotarod. Rotation was turned on with a smooth acceleration (2 rpm/5 sec) beginning 
from 4 rpm to a maximum of 36 rpm (achieved in 1 min 20 sec and maintained for the duration of 
the trial). The latency to fall was measured in sec to a maximum trial time of 5 min. Each animal 
was repeated 3 times with a 5 min rest between trials. The mean of all 3 trials was used for each 
rat. The rotarod used was thoroughly cleaned before and after use with the general virucide 
disinfectant PerCeptTM/MCRTU. Females were tested first, followed by males. Between sexes, the 
room was swept, cleaned, and allowed a 10 min airing-out period before male rats were brought in 









Figure 2-4. The Rotarod. Graphical demonstration of the rotarod enclosure, comprised of an 
elevated rotating beam, used to measure strength, balance, endurance and coordination following 
injury.  
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2.4 Tetrad  
 
The tetrad is a collection of 4 different tasks used to determine cannabinoid-based drug effect in 
the CNS as cannabinoids are known to effect voluntary movement, body temperature, nociception 
and fear-based behaviour in rodents (148). Male and female rats were assigned to volume matched 
i.p. injections of 1 or 10 mg/kg THC or Vehicle as 1:1:18 (ethanol: emulphor: saline) according to 
previous randomization. One hour post TBI, rats were injected and tetrad tests – with the exception 
of the open field described below – were performed following a previously described protocol 
(149), at 6 h, 3 days and 7 days post-injection, prior to rotarod, to determine whether there was any 
indication of lasting cannabinoid receptor-mediated effects Animals were habituated to the 
treatment room and instruments for 3 days prior to data collection. Prior to data collection, rats 
were habituated in a neighboring room for minimum of 10 min prior to a 5 min procedure room 
habituation. It should be noted that CB1R activation commonly produces a hypolocomotive 
response (150). Therefore, the tetrad was also selected in order to verify that no significant drug 
effects were confounding the locomotor performance of the rats (151).  
 
2.4.1 Catalepsy  
 
To test catalepsy, rats were placed such that their forepaws rested on a 0.7 cm diameter bar 4.5 cm 
above a clean table. The amount of time spent holding the bar was recorded up to a 60 sec threshold. 
Time was stopped when the rat moved off of the bar or when the rat moved their head to the left 
or the right (Figure 2-5). Three trials were performed on each measurement day, and the mean was 
collected.   
 
2.4.2 Body Temperature 
 
Body temperature was measured with a rectal thermometer (Thermalert TH-5, PhysitempTM) 10 
min after catalepsy was tested. VaselineTM was used to facilitate insertion of probe to the 
appropriate depth. Once a stable temperature recording was collected, the probe was removed and 




2.4.3 Tail Flick  
 
Anti-nociception was measured 15 min after catalepsy using the Tail Flick Analgesia Meter (Series 
8, IITC Life Science). Rats were wrapped in a towel and positioned such that the heat light shone 
at 5 cm from the base of the tail. Time to tail removal was recorded up to a 20 s threshold (Figure 
2-6).  
 
2.4.4. Open Field Test (OFT):  
 
The OFT is a measure of locomotion activity and used to interpret levels of anxiety by making use 
of rodents’ aversion to open environments (90). This test is generally performed directly after the 
tail flick, but due to equipment scheduling as well as the OFT being a go-to measure of fear-based 
behaviour in TBI, OFT measures were collected separately from the other tetrad measures, but 
analyzed similarly. OFT baseline was collected on day -1 and experimental data was collected on 
days 1, 4, and 6 following TBI, as indicated in Figure 2-7.  Animals were habituated to the treatment 
room for 2 days prior to data collection. Prior to data collection, all rats were habituated in a 
neighboring room for a minimum of 10 min before being transferred into the OFT room for 5 min 
of habituation before OFT.  The OF chamber (diameter 1.5 m, inner area diameter 1 m) was swept 
and thoroughly cleaned with 40% ethanol by sponge and allowed to air-dry before and after each 
animal. Four floor lamps were turned on, and overhead lights were dimmed. Rats were placed in 
the open field for 10 min, and total movement was recorded using a video camera suspended from 
the roof. Locomotor movement was tracked using Ethovision XT (Noldus). Female rats were tested 
first, followed by male rats. Between sexes, the room was swept, cleaned and allowed a 10 min 




Figure 2-5. Catalepsy. The bar hold test is used to functionally assess cannabinoid-mediated 






Figure 2-6. Tail Flick.  This test is used to measure the impact of cannabinoids on spinal-







Figure 2-7. Open Field. A test used to quantify locomotive and associated fear-based behavioural 
phenotypes in rodents. Rodents have a natural tendency to explore novel spaces and will 
preferentially stick to the parameter of an enclosure to stay hidden. Time spent in the center and 
total locomotion can give indication of anxiety-like behaviour of a rodent. Increased time spent in 
the center and lower locomotor activity indicate a decrease in anxiety-like behavior. Figure created 
by author. 
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2.5 Y-Maze  
 
Y-maze is a preliminary tool frequently used to detect overt changes in working and spatial 
memory (152) (Figure 2-8). This test is based on assumptions made about exploratory behavior of 
rodents exposed to a novel habitat. When placed in the Y-maze, a healthy rodent will normally 
explore the least explored area, resulting in an increased alternation ratio between arms of the Y-
maze (153). The Y-maze consists of 3 arms equally separated at 120° from one another. Animals 
were habituated to the treatment room for 1 day prior to data collection. All equipment was cleaned 
with 70% ethanol before and after each animal and allowed to air dry to mitigate odors between 
sessions. Female rats were trained and tested before male rats. Equipment was cleaned and room 
was allowed to air out for 10 min between sexes. A baseline measure was established on day -1 
pre-TBI.  Rats are put into a different arm for each recording session as per the established timeline 
(Figure 2-3) and recorded for 8 min. Videos were recorded by a video camera suspended from the 
roof. Videos were hand scored and the percentage of spontaneous alternations as well as the number 
of entries into each arm were calculated. The percentage of alternation is equal to the number of 
correct alternations demonstrated in figure 11A, divided by the total number of entries multiplied 
by 100. Videos were also analyzed to obtain total locomotion using Ethovision XT (Noldus). The 











Figure 2-8. Y-maze Spontaneous Alternations. Rodents have a natural inclination to explore 
novel environments. The Y-maze is used to detect overt changes in rodent working memory.   
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2.6 Experimental Design  
 
2.6.1 TBI Method Validation: Pilot Experiment and CT Scans 
 
A pilot study (n=6) was conducted first for experimental calibration using the protocol listed above 
with conditions of 300 g dropped from 1 m. Animals were euthanized with isoflurane (5%) and 
assessed for cranial microfracture by computerized tomography (CT) at the cyclotron facility 
(Fedoruk Center, University of Saskatchewan). CT images were acquired using the VECTor4CT 
(MILabs), with a source of voltage of 55 kV and a current of 0.27 mA with a scan angle set to full 
and scan mode accurate. Reconstruction of each scan was performed using PMOD V3.703, and 3D 
images were rendered using AMIRA (2019.1). According to the images collected, there were no 
signs of overt microfractures occurring at 300 g x 1 m, indicating the magnitude of injury sustained 































Figure 2-9. CT Images of Rat Skull Post- TBI.  Representative images for method validation of 
6 pilot rats used to determine the occurrence of microfractures from the modified weight drop 





Four cohorts of 4-5 males and 4-5 female Sprague-Dawley rats were utilized for this study (total 
animals = 34). Upon arrival at the Lab Animal Services Unit (LASU), animals were acclimatized 
for a 7-day period without handling. The rats were housed in pairs in green-transparent plastic 
temperature-controlled cages and maintained on a standard 12:12 light dark cycle throughout the 
length of the experiment. Following initial acclimatization, animals were handled for 7 days prior 
to commencement of experimentation. Prior to formal training on specific tasks, rats were 
extensively held and handled for 2 days in the rat suite, where TBI and injections would take place. 
On day 3 of acclimatization, rats were transported through the vivarium by cart to the hallway of 
the behaviour suits via the elevator and left to acclimatize for 45 min in the behaviour hallway, 
adjoining behaviour suits. Day 4, rats were once again brought to the behavior hallway, left for 15 
to 30 min, and then transported into the allocated testing room for 10 min with all equipment 
running. Day 5, rats were left for 10 min in the behaviour hallways, transported into the testing 
room and left for 10 min. Rats were then individually placed in bottom of the Rotarod for 2 min. 
Day 6 and 7 followed the same 10 min and 10 min protocol from Day 5, but on Day 6 rats were 
placed for the first time on a moving rotarod. On Day 7, rats were placed on a moving rotarod three 
times, following the established rotarod protocol, but no measures were collected.  Day 7 was the 
last day of formal acclimatization. For all following days of training, testing and treatment, rats 
were left in the behaviour hallway to acclimatize for 10-15 min and then transported into the testing 
room for 10 min. Following acclimatization, rats were pre-trained for 4 days on the rotarod and a 
pre-injury baseline measure was collected one day before TBI. Baseline measures were also 
collected for Y-maze one day prior to TBI, for tetrad 2 days prior, and for OFT 3 days prior to TBI 
(Figure 2-3).   
 
Rats from 3 of the 4 cohorts were randomly assigned into 4 experimental groups of 9 rats (4-5 male 
and 4-5 female): (1) Sham TBI treatment (anesthetized with isoflurane) + i.p. vehicle injection 
[ethanol: emulphor: saline (1:1:18)]; (2) Sham TBI treatment + THC [i.p. injection 1 mg/kg]; (3) 
TBI (under isoflurane anesthesia) + i.p. vehicle injection; (4) TBI + 1 mg/kg THC group: TBI + 
i.p. THC.  These 3 cohorts were subjected to the battery of behavioural measures including Y-
maze, Tetrad, and Rotarod. For the 4th cohort, 10 rats (2-3 male and 2-3 female) were randomly 
assigned to 2 experimental groups: (1) TBI treatment (anesthetized with isoflurane) + 
intraperitoneal (i.p.) vehicle injection [ethanol: emulphor: saline (1:1:18)] or (2) TBI treatment 
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(anesthetized with isoflurane) + i.p. THC (10mg/kg). Rotarod was selected as the only behavioural 
measure to be administered for the 4th cohort.  
 
The observer assessing the rats post-treatment was blinded to the treatment type. Purified THC 
(98%) was sourced from Aurora Cannabis, Saskatoon, Saskatchewan.  In past experiments with 
rats, 1 mg/kg THC i.p., as per the first experiment, represents an approximate ED50 dose (i.e. 50% 
maximal effect) (154), and acted as a therapeutic dose for neuroprotection without adverse side 
effects classically associated with higher doses of THC (155).  
 
A 10 mg/kg dose, as per the second experiment, produces cannabinoid receptor-dependent effects 
(hypolocomotion, reduced anxiety, reduced body temperature) but effects remain non-toxic, unlike 





2.7 Statistical Analysis 
 
In order to determine the effect of 1 mg/kg of THC and TBI on all measures of catalepsy, body 
temperature and anti-nociception, data (n=4-5/group) were separated for sex due to known 
locomotor, temperature, and nociceptive differences between males and females, and analyzed 
according to 2 two-way repeated measures (RM) analysis of variance (ANOVA) test, 2x2 
completely randomized design. Data for OFT (total movement and time in center) were normalized 
as a measure of fold change from the baseline measure for each subject and analyzed according to 
a three-way RM ANOVA, 2x2x2 completely randomised design. Y-maze percentage correct 
alternations were analyzed according to a three-way repeated measure ANOVA, 2x2x2 
randomized design.  Rotarod for the 1 mg/kg THC group Rotarod was normalized as a measure of 
fold change from mean baseline (days -4 to -1), and then analyzed according to a three-way 
ANOVA, 2x2x2 completely randomized design. Normalization was performed to account for 
biological variability in performance between animals and account for scale differences, so all 
animals appear to have the same starting point. When necessary, data was broken down for sex or 
injury and follow-up analyses were conducted using two-way ANOVA, 2x2 completely 
randomized design, when time was not considered a significant factor. The 10 mg/kg THC 
experiment (n=4-5) was analyzed according to a one-way RM ANOVA. Correction for multiple 
comparisons was done using Tukey’s post-hoc analysis. Data is presented as mean ± standard error 
of the mean (SEM) from each group for 1 mg/kg THC experiment and for 10 mg/kg THC 
experiment, *p £ 0.05 is considered statistically significant. All data was analyzed using GraphPad 















The tetrad test consists of bar holding, body temperature, tail flick, and open field assays and is 
used to assess the most-common physiological and behavioural responses to CB1R agonists: 
catalepsy, hypothermia, anti-nociception, and hypolocomotion and anxiety (both in the open field), 
respectively. To determine whether there was a significant effect of TBI or 1 mg/kg i.p. THC 
administered on day 0 on animal physiology and behaviour, the tetrad tests were administered, and 
data was separately analyzed for sex.  
 
According to the two-way RM ANOVA of male catalepsy, sphericity was not assumed 
(Mauchley’s: p<0.001), time was not significant (Greenhouse-Geisser: p=0.58) and there was no 
significant interaction or main effects of injury or drug on measures of catalepsy (two-way RM 
ANOVA: F1 = 0.063, p=0.81) (Figure 3-1A). For females, sphericity was assumed (Mauchley’s: 
p=0.077), time was not significant (p=0.85), and there was no significant interaction or main effects 
of injury or drug on measure of catalepsy (two-way RM ANOVA: F1=0.38, p= 0.55) (Figure 3-
1B).This analysis indicates that neither THC or TBI had a significant effect on catalepsy in male 
and female rats.  
 
For both male and female measures of body temperature, sphericity was assumed (Mauchley’s 
Male: p=0.26; Female: p=0.22) and time was significant (p<0.024) but neither males of females 
exhibited any interaction or main effects of injury or drug treatment on body temperature (two-way 
RM ANOVA Male: F1=0.93, =0.35; Female: F1= 0.64, p= 0.44) (Figure 3-1C, D). This analysis 
indicates that neither THC or TBI had a significant effect on body temperature in male and female 
rats.  
 
In the tail flick assessment anti-nociception, sphericity was assumed for both sexes (Mauchley’s 
Male: p=0.96; Female: p=0.68), time was not significant (p>0.39) and there was no significant 
interaction or main effects of injury or drug on latency to tail flick (two-way RM ANOVA Male: 
F1=0.21, p=0.65; Female: F1=0.34, p=0.57) (Figure 3-1E, F).  These results indicate that there was 
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no significant effect of THC or TBI on nociception as assessed by the tail flick assay.  
 
Locomotion was assessed by total movement in the open field. Anxiety-modelling effects were 
measured by time in the central quadrant of the open field. The data are described elsewhere 
because open field tests were conducted on different days from the bar-holding, body temperature 
and tail flick assays (Figure 2-3). 
 
Overall, catalepsy, body temperature, and tail flick assessments indicate that 1 mg/kg THC 
administered i.p. did not evoke cannabinoid-dependent effects in rats whether they received TBI 
or not and TBI did not alter THC-dependent effects in these tests. Although THC administered 
acutely at this dose has been shown previously to produce tetrad effects (148), we did not detect 
such effects here. This may be because tetrad assessments took place hours and days after drug 






Figure 3-1. Assessment of catalepsy, body temperature, and nociception in rats following TBI 
and 1 mg/kg THC treatment. Seventeen Sprague-Dawley rats of both sexes were administered a 
Sham-TBI or TBI and injected with 1 mg/kg THC i.p. or Vehicle. 1 mg/kg THC i.p. nor TBI 
significantly induced catalepsy in males (A) or females (B). 1 mg/kg THC i.p. nor TBI significantly 
lowered body temperature in males (C). or females (D). 1 mg/kg THC i.p. nor TBI significantly 
effect tail flick responsiveness in males (E) or females (F). Data presented as mean ± S.E.M. n=4-
5 per group (males and females). Statistical analyses were two-way RM ANOVA.  
  







































































































































3.2 Open Field 
 
In order to determine whether 1 mg/kg THC and TBI effected total locomotion or fear-behaviour 
in rats, the OFT was conducted to measure total movement and time spent in the center of the open 
field as a model for anxious or fearful behaviour in rats.  
 
3.2.1 Measure of Total Locomotion  
 
Total movement in the OFT (measured in m) was normalized to the baseline measurement taken 
prior to TBI. Normalized data were analyzed according using three-way RM ANOVA. 
Assumptions of sphericity were not met (Mauchley’s: p=0.003). Time was significant 
(Greenhouse-Geisser: p=0.022); however, no main effects of sex, injury, or drug treatment, or 
interactions between these variables were detected (three-way RM ANOVA: F1,28=0.056, p=0.81) 
(Figure 3-2). These results indicate no significant effect of TBI or THC on total locomotor 
behaviour in male and female rats.  
 
3.2.2 Time in Center Quadrant 
 
Time spent in the center quadrant of the OFT was normalized to the baseline measurement taken 
prior to TBI and analyzed according to a three-way RM ANOVA. Assumptions of sphericity were 
not met (Mauchley’s: p<0.001). Time was considered significant (Greenhouse-Geisser: p=0.034); 
however no main effects of sex, injury, or drug treatment, or interactions between these variables 
were detected (three-way RM ANOVA: F1,28=1.38, p=0.25) (Figure 3-3). These results indicate no 
significant effect of TBI or THC on time spent in the center quadrant between male and female 
rats.  
 
As with catalepsy, body temperature, and nociception, data from the OFT demonstrates that 1 
mg/kg THC administered i.p. did not produce cannabinoid-dependent reductions in locomotion or 
anxiety-like behaviour. Although acute treatment with 1 mg/kg THC has been shown previously 
to reduce movement and anxiety (148), these were not detected here. Despite this, conducting these 
tetrad analyses was crucial to determine whether cannabinoid-mediated intoxication had occurred 







Figure 3-2. Assessment of total locomotion in the open field test following TBI and 1 mg/kg 
THC treatment. Seventeen Sprague-Dawley rats of both sexes were administered a Sham-TBI or 
TBI and injected with 1 mg/kg THC i.p. or Vehicle. 1 mg/kg THC i.p. nor TBI significantly 
impacted total locomotion of male of female rats. Data is normalized as a fold change from baseline 
and displayed by sex, (A) Male (B) Female. Data presented as mean ± S.E.M. n=4-5 per group 
(males and females). Statistical analyses were three-way RM ANOVA.  
  















































































Figure 3-3. Assessment of time spent in the center quadrant of the open field following TBI 
and 1 mg/kg THC treatment.Seventeen Sprague-Dawley rats of both sexes were administered a 
Sham-TBI or TBI and injected with 1 mg/kg THC i.p. or Vehicle. 1 mg/kg THC i.p. nor TBI 
significantly impacted time spent in the center quadrant of male of female rats. Data is normalized 
as a fold change from baseline and displayed by sex, (A) Male (B) Female. Data presented as mean 
± S.E.M. n=4-5 per group (males and females). Statistical analyses were three-way RM ANOVA.  
  






































































3.3 Y-Maze Percentage Spontaneous Alternations 
 
Y-maze is a measure of overt changes in spatial working memory. In order to determine the effect 
of 1 mg/kg THC and TBI effect on working memory, the percentage of correct alternations between 
all 3 arms of the Y-maze were analyzed. Data met assumptions of sphericity (Mauchly’s: p=0.93) 
and the results from the three-way RM ANOVA on percentage correct alternations of male and 
female data indicated time was significant (p= 0.048) but no significant main effects of sex, injury, 
or treatment, or interactions between these variables were detected (three-way RM ANOVA: 
F1,27=0.022, p=0.88) (Figure 3-4).  
 
For analysis of total arm entries in the Y-maze, data met assumptions of sphericity (Mauchly’s: 
p=0.29), and the results from the three-way RM ANOVA indicate that  time was significant (p= 
0.001), and sex was considered a main effect (three-way RM ANOVA: F1,27=6.453, p=0.017).  No 
other main effects or interactions between sex, injury or treatment were considered significant 
(three-way RM ANOVA: F1,27=0.036, p=0.85) (Figure 3-5). Therefore, neither TBI or THC 
treatment had an overt effect on locomotion, which is in line with our data in the OFT (Figure 14), 
but females consistently entered more arms than males did. One female Sham TBI + VEH was 
removed from the analysis due to a breach of test parameters, when the rat jumped out of the maze. 
This analysis indicates that Y-maze total number of total arm entries significantly differed between 
sexes, but TBI or THC played no part in this effect. It can therefore be concluded that, neither 1 









Figure 3-4. Assessment of working memory through measurement of spontaneous 
alternations in the Y-maze task following administration of TBI or treatment with 1 mg/kg 
THC. Seventeen Sprague-Dawley rats of both sexes were treated with a Sham-TBI or TBI and 
injected with 1 mg/kg THC i.p. or Vehicle. Sex, 1 mg/kg THC i.p. nor TBI significantly impacted 
performance on Y-maze. Data is displayed by sex, (A) Male (B) Female. Data presented as mean 































































Figure 3-5. Total number of male and female Y-maze arm entries. This figure illustrates the 
mean number of arm entries by each treatment group across the experimental timeline. 1 mg/kg 
THC i.p. nor TBI significantly impacted total number of arm entries for Y-maze, but there was a 
significant difference between males and females as determined via three-way RM ANOVA: 
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3.4.1 Treatment with 1 mg/kg THC  
 
Rotarod is a commonly used behavioural used to asses higher-level motor function in rodents 
following TBI. In order to determine the effect of 1mg/kg THC and TBI on rotarod, data was 
normalized relative to the mean of baseline measurements taken prior to TBI, expressed as fold 
change relative to this mean, and analyzed via a three-way repeated measures ANOVA. One male 
Sham-TBI + VEH was removed from the assessment after an outlier’s analysis was performed 
(observation was greater than 2 SD from the group mean). Data did not meet assumptions of 
sphericity (Mauchly’s: p<0.001). Time was not considered significant (Greenhouse-Geisser: 
p=0.29) (Figure 3-6). According to the analysis, there was no significant three-way interaction 
between sex, injury, and treatment: (three-way RM ANOVA: F1,27=3.65, p=0. 67), but the analysis 
indicated a significant interaction between sex and injury (three-way RM ANOVA: F1,27=0.01) 
(Figure 3-7A). These results indicate that males and females reacted significantly differently to 
injury. THC and vehicle treatment data were aggregated and compared between sexes and injury 
using a two-way ANOVA (Figure 3-7B). The two-way ANOVA indicated a significant interaction 
between sex and injury (two-way ANOVA=F1,32=10.03, p= 0.0034), but the Tukey post-hoc 
indicated no significant differences between groups (Figure 3-7B). Based on this analysis, data was 
segregated by sex and 2, two-way ANOVAs were conducted for male and female data separately.  
 
The two-way ANOVA of male data indicated a main effect of injury (two-way ANOVA: 
F1,14=11.27, p=0.0047) and no significant interaction between injury and drug (Figure 3-7C). The 
Tukey post hoc however indicated significant differences between Sham-TBI + VEH vs. TBI + 
VEH (p= 0.01), Sham-TBI + VEH vs. TBI + THC (p=0.01), and Sham-TBI+ VEH vs.  Sham-
TBI+THC(p=0.049), Figure 3-7C. Therefore, these results indicate that TBI robustly reduced 
rotarod performance in both VEH and THC treated groups, and THC treatment of non-injured rats 
reduced latency to fall in comparison to controls. 
 
 The two-way ANOVA of female data indicated no significant main effects of injury or drug and 
no interactions between these variable (two-way ANOVA: F1,13=3.14=0.10) (Figure 3-7D). 
Interestingly, this indicates that female performance on the rotarod was not significantly changed 
by TBI or THC.  
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Based on these results, TBI significantly reduced motor coordination in male rats but had no effect 
in female rats, and THC measurably decreased motor coordination in non-injured male rats 
compared to vehicle controls, an effect that was not present in their injured counterparts or in 
female rats. Moreover, the magnitude of the injury did not significantly change over the course of 
the study because time was not significant in our analyses. Similarly, THC treatment did not alter 
rotarod performance in rats with or without TBI. These results differ from our initial hypothesis in 
that we expected both TBI and THC to have a significant effect on recovery in both male and 
female rats. importantly, the data clearly indicate the TBI altered behaviour and motor performance 
in a sex-dependent manner and support the use of this model for TBI in rats (90). Given the absence 
of clear effect brought about by THC treatment in these assessments, we next chose to test a higher 








Figure 3-6. Visualization of rotarod data by day following administration of TBI or treatment 
with 1 mg/kg THC. Seventeen Sprague-Dawley rats of both sexes were treated with a Sham-TBI 
or TBI and injected with 1 mg/kg THC i.p. or Vehicle. Data is displayed by sex, (A) Male (B) 
Female. Because time was not found to have a significant effect, statistical analyses were conducted 
between group means and are displayed in figure 19. Data are presented as mean ± S.E.M. n=4-5 
per group (males and females).   
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Figure 3-7.The effect of 1 mg/kg THC and TBI on male vs. female rotarod latency to fall. 
Seventeen Sprague-Dawley rats of both sexes were treated with a Sham-TBI or TBI and injected 
with 1 mg/kg THC i.p. or Vehicle. (A) Data are displayed by treatment group where (*) indicates 
a significant interaction between sex and injury (p<0.05), as determined via three-way RM 
ANOVA. Data are presented as mean ± S.E.M. n=4-5 per group (males and females). (B) Data are 
displayed with vehicle and THC treatment aggregated for a comparison of sex and injury. Data are 
presented as mean ± S.E.M. n=8-10 per group (males and females), Analysis was done by two-
way ANOVA. Data are displayed by sex for males (C) and (D) females. (C) TBI decreased rotarod 
performance in male TBI rats compared to Sham-TBI controls, and THC decreased rotarod 
performance in Sham-TBI rats compared to Sham-TBI rats treated with vehicle. (D) Neither TBI 
or THC altered rotarod performance in female rats. Data are presented as mean ± S.E.M. n=4-5 per 
group (males and females). Analyses were done by two-way ANOVA followed by Tukey’s post-








































































































































3.4.2. Treatment with 10mg/kg THC 
 
In order to assess the effect of THC and TBI on latency to fall further, a higher dose of THC was 
used. Male and female rats were treated with 10 mg/kg THC + TBI or TBI + VEH. Data were not 
separated according to sex because too few animals of either sex were utilized. A one-way RM 
ANOVA was performed. According to the analysis, assumptions of sphericity were not met 
(Mauchley’s: p< 0.001). Time was considered significant, (Greenhouse-Geisser: p=0.025), but 
according to the one-way RM ANOVA THC treatment was not significant (one-way RM ANOVA: 
F1,8= 0.449, p=0.52) (Figure 3-8). Therefore, a greater dose of THC that approximates an ED80 
(150) failed to produce a significant effect on rotarod performance in Sham and TBI rats. Given 
the small sample size of these data and inability to segregate data on the basis of sex, future studies 
with larger group sizes are warranted to fully understand how higher THC doses may alter rotarod 
















Figure 3-8. Assessment of 10 mg/kg of THC and TBI on combined male and female rotarod 
latency to fall. Five Sprague-Dawley rats (male and female, data not segregated by sex) were 
treated with a TBI and injected with 10 mg/kg THC i.p. or Vehicle. Analysis of normalized data 
indicated no significant difference between treatment groups across experimental timeline. Data 
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Chapter 4 Discussion 
 
4.1 Hypothesis of this Research 
 
The data described here provide novel information regarding the effects of THC on the modulation 
of the ECS following mTBI in male and female rats. We postulated that the treatment of rats 
subjected to TBI and THC 1 h post-injury would restore motor function and improve behavioural 
profiles of injured rats across the experimental timeline.  
 
Our results show that 1 mg/kg of THC and TBI did not alter catalepsy, body temperature, or anti-
nociception and failed to impact open field total locomotion or time spent in the center quadrant. 
In contrast, both THC and TBI demonstrated sex specific differences in rotarod performance as 
measured by latency to fall. In males, THC and TBI independently reduced performance on the 
rotarod in males, but THC did not enhance or diminish rotarod performance in injured male rats. 
In females, neither THC or TBI altered rotarod performance. Therefore, our initial results do not 
agree with our hypothesis because THC treatment did not restore motor function or improve 
the rat’s behavioural profiles. On the contrary, THC itself was deleterious to male rotarod 
performance and neither beneficial or detrimental in injured male and female rats. Moreover, 
we anticipated a symmetrical effect of TBI on rotarod in both males and females and potential sex-
dependent differences in response to 1 mg/kg THC; however, male and female rats responded 
differently to our TBI model and THC, demonstrating potential sex-dependent differences in both 
that must be accounted for in future research.  
 
Importantly, we observed that our TBI model produced a sustained reduction in higher level 
locomotor function in the rotarod test in male rats – demonstrating the validity of this model (143) 





4.2 Tetrad  
 
The tetrad battery of tests was selected in order to identify any lasting cannabinoid-based impact 
on animal physiology. The tests were strategically implemented to identify any lasting cannabinoid 
activity in areas of the CNS where CB1R are most abundant that could interfere with other 
behavioural measures. Non-significant catalepsy, body temperature and anti-nociceptive results 
held true to our expectations, as these tests measure acute effect of cannabinoids which generally 
peak at 30 mins following an i.p. injection in rodents (156). Importantly, these tests also served as 
confirmation that TBI had no measurable effect on catalepsy, body temperature and anti-
nociception of the rodents 1 h out of administration that could have confounded other behavioural 
measures.  
 
OFT is a measure frequently used in pre-clinical research to assess locomotion and anxiety-like 
behaviours in rodents via the quantification of total locomotion and time spent in the center 
quadrant that can be present due to both cannabinoid-based drug effect as well as TBI. Anxiety 
like-behaviour manifests acutely following TBI in rodents and humans as well as acting as a 
common symptom of chronic post-concussive symptoms (157). For this reason, according to our 
hypothesis, we expected to see measurable deficits in OFT of total distance traveled following TBI, 
but there were no measurable or visual changes in data during the experimental timeline. This 
disconnect between observed and expected results may have to do with the injury magnitude. Quite 
simply, the injury incurred may have been too subtle to produce persistent large-scale changes of 
fear-based behaviour in rodents detectable in 10 min measures of OFT. Given these results, there 
are a few modifications to consider for future experimentation.  To detect more subtle injury and 
drug induced behaviours, it is imperative to modify test parameters, for example, implementing 
longer recording time  (>10 min), increasing or decreasing the light or environmental stimulus or 
plainly substituting more complex behaviour measures could serve as beneficial modification to 






Y-maze percentage correct alternations is a behavioural modality frequently used to assess the 
acute and chronic changes in spatial memory for both TBI and pharmacological investigation in 
rodents (158). Much like the OFT, we expected to see a measurable deficit in Y-maze performance 
following TBI, but there was no significant difference between Sham-TBI and TBI across the 
experimental timeline for percentage correct alternations. This most likely speaks to the lack of 
specificity of the Y-maze, which seems most likely to detect overt changes in behaviour only when 
animals are very ill or heavily affected by pharmacological agents. Importantly, females 
consistently scored higher total number of arm entries in comparison to males, indiscriminate of 
treatment or injury. Although we expected to detect this difference in OFT as well, this difference 
in total Y-maze entries serves to highlighting sex differences in exploratory behaviour. Although 
this test has been applied in evaluating the full spectrum of TBI (86, 166), it may be more suited to 




4.4 1 mg/kg Rotarod 
 
The rotarod is a device that resembles an elevated treadmill for rodents suspended above a sensor 
plate to detect the animal when it falls from the treadmill. In pre-clinical TBI research, the rotarod 
is a commonly used methodology to measure higher level neuromotor capacity such as 
coordination, musculoskeletal strength, endurance, and balance post TBI (159). Interestingly, 
according to the results, sex, injury and drug effect played a significant factor in the performance 
of animals on the rotarod.  
 
More specifically, TBI significantly decreased male latency to fall, but had no comparable effect 
in females.  From a drug effect, the Tukey’s post-hoc analysis revealed that 1 mg/kg THC effected 
Male Sham-TBI groups, as the Sham-TBI + THC groups performed significantly worse on the 
rotarod in comparison to control. This reaction to THC in male Sham-TBI is interesting as it 
reinforces circulating knowledge about sex-dependant modulatory differences in the ECS (160, 
161). THC normalizes glutamate release via CB1R and reduces inflammation via CB2R, which are 
beneficial actions in the event of an injury, but could be intoxicating and detrimental under “normal 
conditions, as seen in results between Sham-TBI + TBI and Sham-TBI+ VEH.   
 
In contrast, female drug treatment approached significance as main effect (p = 0.051). Additionally, 
upon visual inspection of female rotarod data (Figure 19D), the TBI + VEH group shows a non-
significant increase in latency to fall, between TBI + VEH and Sham-TBI groups as well as its 
female TBI+ THC counterpart. Likely, the almost significant p-value from drug effect and the 
difference in performance between female sham-TBI + VEH and Sham groups and TBI+ THC 
may speak to the need to increase group size and tighten the SD to clearly indicate outliers to 




4.5 Rotarod 10 mg/kg  
 
With regard to our supplementary analysis with 10 mg/kg of THC, we hypothesized that 10 mg/kg 
of THC would restore motor function in comparison to a TBI control group. Our results showed 
that the administration of 10 mg/kg of THC did not significantly improve performance of THC 
treated rats on the rotarod in comparison to a vehicle control group. Visual inspection of the data 
according to day (Figure 20) indicates that THC may have offered some therapeutic benefit, as the 
rats treated with THC exhibited a “rebound effect” in their performance on day 1 to 3, performing 
on average 0.5 fold better than the vehicle treated TBI group. Importantly, this data represents 
pooled male and female data, which according to previous analyses of the 1 mg/kg cohort, 
demonstrated significant interactions between sex and injury.  Therefore, an appropriate follow-up 
experiment to this data would be to separate for sex and increase the number of male and female 
subject to fully quantify sex specific reactions to 10 mg/kg THC.  
 
4.6 Sex differences in TBI 
 
In pre-clinical research, females have been known to survive and functionally recover better in 
brain injury than males (162, 163). Administration of exogenous estrogen and progesterone to 
males and ovariectomized females has improved molecular, and histological outcomes (164), but 
behavioural outcomes seem to vary largely according to mechanism of injury. Previous research 
demonstrated that in a model of diffuse TBI, under 3 different anesthetics, female rats consistently 
scored better than males on rotarod, and isoflurane exhibited enhanced neuroprotective properties 
in females more so than males in comparison to pentobarbital and halothane according to results 
on Barnes Maze and OFT (165). In comparison, in a study of CCI, a focal injury administered in 
male and female mice, no differences in comparable behaviour measures were found (166). 
Females may recover function better than males because of antioxidant and anti-inflammatory 
effects of estrogen and progesterone on the preservation of BBB integrity and regulation of edema.  
 
By comparison, clinical observational data indicates that females are known to be at higher risk, 
have poorer outcomes in TBI, and are more likely to report persistent post-concussive symptoms 
(167). This may be due to differences in size as well as sex hormones which may impact recovery 
and influence injury severity,  but also may be influenced by the increased willingness of females 
to report symptoms , as well as perceived social pressures for females to forgo treatment and return 
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to their role as caregivers (168, 169, 170). A large-scale observation study by Davis et al. (2006), 
indicated that when aged-matched, there was no significant difference in recovery between pre-
menopausal females and males, but post-menopausal females recovered better than their male 
counterparts (171). Differences between pre-clinical sex differences in models of TBI and 
observational data in humans on the bases of sex and gender underscore the limitations of animal 
models in studying the complete disease etiology of TBI. Future pre-clinical work that probes more 
subtle behavioural and cognitive changes following injury that were not assessed here would 
provide valuable data for model validation the translational potential of this work.    
 
Most importantly, the robust reaction of males to TBI according to rotarod performance confirm 
the injury model, but specifically highlight the difference in female to male reaction to injury and 
the complexities associated with comparing behavioural data between sexes in preclinical research. 
The discrepancies highlighted between pre-clinical and clinical research indicate the importance of 
continued inclusion of female subjects in future research.  
 
4.7 Sex differences in the Endocannabinoid System 
 
As previously stated, the endocannabinoid system is a complex system within the human body that 
modulates numerous physiological functions such as locomotion, pain, body temperature as well 
as cognitive and behavioural functions (14, 15). With CB1R being the most abundant receptor 
within the CNS, it can be assumed that its relationship with other systems in the human body is 
complex and multifaceted. Current pre-clinical research has reliably shown persistent sex 
differences in cannabinoid-based drug; where females reliably response physiologically and 
behaviourally stronger and faster to lower doses, and exhibit higher plasma concentrations of active 
metabolites (172, 173). As proof of concept, Craft and Leitl (2008), demonstrated that the anti-
nociceptive effects of THC in females fluctuated according to estrus cycle, and were more sensitive 
and different from males between late proestrus and estrus (174). Similarly, increasing estradiol 
was shown to mitigate decreases in body temperature, performance in operant tasks, and 
hyperphagia, associated with cannabinoid exposure (160, 174, 175). From an addictions 
perspective, pre-clinical research has shown that females are at high risk of acquiring and 
reinforcing behaviours associated with cannabinoid abuse (177, 178). Furthermore, sex differences 
have been shown at a cellular level, where female CB1R and male CB1R display significantly 
different binding affinities most notably in the prefrontal cortex, amygdala, hippocampus and 
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cerebellum (179). According to Cooper and Craft (2018), this increase bioavailability and 
associated potency in females is attributed to fundamental sexual differences occurring early in 
development in addition to acute effects of gonadal hormones acting on the system causing lasting 
changes in hormones pharmacokinetics and pharmacodynamics (see 180 for in-depth review). 
Notably, these sex differences are present, but less clear in adolescent animals, which supports the 
relevance of estradiol concentrations to pharmacokinetic and pharmacodynamic differences in 
females (180).  
 
Known behavioural differences between females and males exhibited in this study highlight the 
need for future molecular examination of sex-dependant differences of the ECS and recovery in 
TBI. Mechanisms for these differences are yet unknown, but a study by Xing et al. (2014), who 
used a stress mechanism to modulate the ECS of male and female rats, highlights specific 
differences in CB1R mRNA expression level and protein levels in the prefrontal cortex of stressed 
female rats compared to their male counterparts (182). Their work represents early postulation 
about how these sex- and stress-dependant modulatory changes could participate in resiliency 
following brain injury (182). For this reason, on-going multifaceted investigations of inflammatory 
cytokine profiles, cortical CB1R receptor concentration as well and cortical endocannabinoid 
levels on these animals following injury and administration of 1 mg/kg and 10 mg/kg THC, 
respectively, will provide validity to current behaviour results and elucidate pending modulatory 
sex dependent effects on recovery. 
 
The sex-dependant effects of cannabinoids are consistent in human studies but are reflected in 
different ways. However, data are limited. Clinically, females and males exhibit different use 
patterns for cannabis (180). Women are less likely to gain analgesic benefits from THC, but 
maintain similar abuse criterion (183). As in animal models, human females have high levels and 
greater exposure to THC’s main metabolite 11-OH-THC after oral dose (184). These persistent sex 
differences that translate across both the animal and human development highlight the importance 
and clinical relevance of research with both sexes for therapeutic and addiction purposes.  Research 
has illustrated the complex relationship between sex and TBI, and the endocannabinoid system is 
not absolved from this biological phenomenon therefore emphasising the importance of continued 




4.8 Locomotor Activity 
 
An important distinction to be made in TBI research is the difference between motor function and 
locomotor activity. Motor function speaks to basic neurological function eliciting low level motor 
function following injury. By comparison, locomotor activity speaks to high level locomotor 
capacity associated with health subjects and outcomes where changes in direction, rate changes 
and balance are involved (185). Within pre-clinical data, the lines between these 2 entities often 
blur. Throughout my literature review, due to the blur of distinction across levels of injury severity, 
the language used to describe varying degrees of motor impairment following injury also blurred. 
In order to encourage translation within brain injury research, it is imperative that researchers 
distinguish between high-order locomotor activity and learning required to participate in 
behavioural activities such as the rotarod, versus low level motor function associated with more 
consequential injury phenotypes.  
 
 
4.9 Comparisons to Current Data 
 
Only 1 paper was identified in the literature to date using THC as a pharmacological intervention 
in the treatment of TBI in both male and female rats. This paper, published by Bhatt (2020) (136), 
repeatedly administered a lateral impact method to illicit three diffuse repeated mTBIs (RmTBI) 
using 50 g. In their first experiment, animals were treated with 6 i.p injections of 1.25mg/kg THC, 
and during the last 3 administrations of THC animals received 3 RmTBIs (136). Following 
RmTBIs, behavioural data were collected. Results from the first experiment indicated that THC 
administration increased righting time in rats following TBI as well as persistent sex differences, 
but no other significant differences in THC administered animals (136). For the second experiment, 
3 RmTBIs were administered followed by repeated THC administration for 12 consecutive days 
via i.p injection at a dose of 1.25 mg/kg (136). Animals were then tested to assess neurological 
function, anxiety-like behaviour, short term working memory and depressive-like behaviour (136). 
According to their results, repeated administration of 1.25 mg/kg of THC improves working 
memory in the Novel Object Recognition Test, anxiety-like symptoms in Elevated Plus Maze but 
not OFT, and depressive-like symptoms in Force Swim Test in RmTBI groups (136). Additionally, 
sex and RmTBI interacted for depressive-like symptoms and sex was a main effect for working 
memory (136). Importantly, although this experiment used a completely different battery of 
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behaviour tests from the ones used in this study, the sex differences identified with injury are 
consistent with our experiment, and the more precise models of anxiety and working memory serve 
as a good reference for following experimentation.  
 
The study of Bhatt et al. (2020) demonstrated that post-injury THC was able to rescue the injured 
phenotype symmetrically for males and females in in working memory, and anxiety like behaviour 
(136). Is important to note however that the rats in this study were adolescents when testing 
occurred (post-natal day: 21-55) which is problematic considering the previously highlighted roles 
that estrogen and progesterone can play on TBI resilience, as well as on the formation and 
modulation of the ECS (161).  The comparison between our results and the results from Bhatt et 
al. (2020) indicate that THC can provide therapeutic effect independent of sex when administered 
before sexual maturity, and therefore provides indication that a similar repeated THC 
administration in adult animals is worth performing.   
 
 
4.10 Limitations  
 
According to our results, the existing experimental design did not provide as forthright a 
behavioural response as anticipated, indicating that further research is required to determine 
potential avenues of change in the ECS following TBI. More specifically, the inclusion of more 
precise behavioural and neurological assessment tools is critical to increase the precision of mTBI 
appraisal, increasing the n for both groups, as well as the continued inclusion and further 
investigation of TBI- and ECS-based sex differences. Above all, it is important to note the 
limitations the low number of test subjects in the 10 mg/kg experiment presented. Each group had 
an n=5 combined males and females, and based off of the sex differences brought to light from the 
rotarod,  it is imperative to analyze them separately. Sex desegregated data in mTBI research is 
sorely lacking (86, 186) and according to a review by Fattore and Fratta (2010), cannabinoid 
research is not absolved from this problem (187). The differences seen between sexes in the 1 
mg/kg experiment amongst rotarod measures indicate that pooled data does not accurately paint 
the whole data picture.  
 
Firstly, the substitution of more sensitive assessment tools to accurately gauge subtle forms of 
physiological and cognitive change associated with mTBI are necessary as follow-up analysis to 
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this study. Despite the frequent use of the Y-maze for cognitive assessment following brain injury, 
the injury model in this study may not have been severe enough to elicit overt cognitive changes 
required for detection in the Y-maze test of percentage correct alterations. Inclusion of more 
focused assessment tools providing a multi-faceted investigation of memory and cognition such as 
novel object recognition, Barnes maze, sociability, and valuable gold standard tools such as trial 
unique non-matching to location task (TUNL) and 5-Choice Serial Reaction Time Task (5-CSRTT) 
(188, 188) would serve to enhance the understanding and translation of more subtle acute and 
chronic behaviour changes associated with mTBI.  
 
In addition to quantifying cognitive changes, neurological symptoms were assessed using the 
rotarod. Recent evidence indicates that exercise activates the ECS and contributes to physiological 
and psychological adaptations consistent with regular physical activity (190). Over the last several 
decades, exercise has become recognized as a therapeutic agent. As a general lifestyle intervention, 
exercise is known to increase mitochondrial function and endorphin levels, increase cerebral blood 
flow and cognitive performance, regulate neurotransmitter levels, and decrease inflammation (191, 
192). Exercise facilitates recovery when implemented pre-TBI (193), immediately post-TBI (194), 
as well as weeks after the initial injury (195) in both animal models and human studies. Several 
studies indicate that endogenous cannabinoids are upregulated post-exercise and contribute to 
exercise induced analgesia, also known as “runners high” (196, 197). Since exercise is therapeutic 
in TBI models on its own, the combination of exercise and cannabinoid-based therapeutics may 
provide additive or synergistic benefit. Therefore, the administration of rotarod as a behavioural 
measure in this study may have blunted the detection of more sensitive behavioural symptoms by 
providing enhanced recovery rates, such as OFT or Y-maze. For this reason, in follow up 
investigation, non-confounding assessments of neurological function, such as beam walk or reflex 
testing (76, 198), could serve as effective means of detecting subtle and acute changes in 
neurological function that may resolve quickly following injury, especially when paired with 
exercise.  
 
Another consideration is the role of the ECS in circadian rhythm disruption frequently associated 
with mTBI. Symptoms of sleep/wake disturbances following injury range in severity and can play 
a significant role in patient outcomes and quality of life (199-200). In terms of mTBI, a review of 
cannabis and cannabinoids on sleep by Babson et al. (2017) indicated that acute THC use can 
improve latency to sleep and frequency of wake after sleep onset (201). That same review 
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highlighted research indicating that low dose CBD supports wakefulness and high dose CBD 
improves latency to sleep. Therefore, the inclusion of sleep wave analysis via EEG to monitor the 
more subtle impacts of cannabinoid administration on sleep quality, wakefulness, and recovery of 
injured animals merits investigation.  
 
4.11 Future Directions 
 
In order to build on the findings described here, various avenues of investigation should be 
addressed. From a brain injury perspective, the injury mechanism, frequency, and severity all 
supply possible opportunities for exploration as well as the investigation of other potentially 
therapeutic cannabinoids, different dosing regimens, unexamined therapeutic avenues of 
cannabinoids, and most importantly, the continued prioritization of sex desegregated data.  
 
Injury magnitude and frequency of injury deserve additional investigation given the inconsistency 
of injury severity classification within the mTBI research field. As mentioned previously, to date, 
pre-clinical TBI researchers using variations of the weight drop model have classified injuries as 
mild when dropping a weight ranging between 10 g and 1600 g (86). Moreover, CCI, another injury 
model highlighted earlier has its own methods for classifying injury severity, and it classifies an 
impact as mild when a craniotomy is performed, and an impact administered by a 3.0 mm steel tip, 
driven into the brain at 5.0 m/s, to a depth of 1 mm, resulting in significant visual and behavioural 
abnormality upon examination (166).  In a clinical setting, mild TBIs are characterized by 
functional abnormalities without the presence of structural abnormalities. When structural 
abnormalities are present, the injury is then classified as a moderate TBI (12, 59). This limited 
comparison within and between injury methods indicates that mild to moderate brain injury 
classification vary significantly across pre-clinical investigations, and these differences dilute 
behavioural data due to misalignment of translation and ultimately misrepresents applicable 
knowledge to the clinical field. 
 
Modification of the injury mechanism and the use of anesthetic are worth examination. Anesthetic, 
more specifically isoflurane, is neuroprotective with administration pre-injury (202, 145), and is 
simply not part of normal sport or motor vehicle mechanism of injury. Within models of severe 
TBI, isoflurane’s neuroprotective properties may not be considered significant given the depths of 
the injury, but within a mild to moderate TBI model, this may account for the lack of significance 
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within the OFT measures and Y-maze % alternations.  Consequently, a novel model of conscious 
mTBI where no anesthetic is used, such as the one developed by Pham et al. (2019) (203), warrants 
consideration.  
 
In terms of ECS modulation, THC was selected as the treatment because it is the most abundant 
cannabinoid found in Cannabis sativa plant, and it possesses potential neuroprotective and anti-
inflammatory potential thanks to its unique pharmacology.  Yet it’s psychoactive component makes 
potentially less suitable intervention in a clinical setting. Due to the overarching lack of research 
examining the modulatory effect of various phytocannabinoids in TBI, and THC’s promising 
CB1R and CB2R pharmacology, THC served as a perfect candidate to begin these studies. One 
and 10 mg/kg were selected as appropriate doses thanks to aforementioned dose response curves 
from i.p injection resulting in ED50 and ED80 respectively, and therefore established a starting point 
(154, 155). Regarding the experimental timeline, THC was administered in a single dose following 
injury. As immune activation is present for weeks to months following injury (83) exploration of 
diverse dosing regimens post injury targeting chronic secondary injury mechanisms is necessary. 
Quite simply, 1 dose of THC represented a necessary starting point for this research but may not 
have been enough to elicit a lasting therapeutic response. Additionally, i.p injection is not the main 
mode of administration for cannabinoids when used in a recreational setting, thus emphasizing the 
importance of investigating smoked, vaped and oral administration of cannabis flower and oil in 
an injury model. Future research in this area could therefore utilize chronic daily dosing regimens 
through inhalation or oral routes of exposure.  
 
Previous research highlighted in review by Singh and Neary (2020) shows promise for other 
cannabinoids such as CBD for endocannabinoid and non-cannabinoid-based modulation in the 
treatment of post-traumatic inflammation, cerebrovascular dysregulation, ROS accumulation and 
epithelial disruption via TRPV-1, 5-hydroxytryptamine receptors (5-HT1A), PPARγ, and 
adenosine receptors (204). Preliminary data shows that when administered together, CBD and THC 
elicit significantly different behavioural and metabolic effects than when administered alone (205), 
potential due in part to dual modulation of CB1R and CB2R in addition to other remote and lesser 
explored receptor targets. CBD alone also deserved future exploration due to its activity at CB2R, 
who’s activity has already been shown to produce robust CNS anti-inflammatory activity (103, 
206, 207). A point of interest emerging from the results of CARE-E trials of pediatric treatment-
resistant epilepsy by Huntsman et al. (2019) have found that a 1:20 ratio of THC to CBD using 
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whole plant extract is more effective than its isolated counterpart, suggesting potential entourage 
effects of lesser-known cannabinoids that could translate to TBI-induced excitotoxicity and 
seizures (208). As this available information suggests a plethora of pharmacotherapeutic avenues 
of cannabinoids deserving of investigation.  
 
4.12 Conclusion  
 
The TBI model used in this study decreased rotarod performance for male and not female rats, but 
did not impact performance in the OFT or Y-maze. THC treatment decreased rotarod performance 
in Sham-TBI male rats compared to Sham-TBI male rats treated with vehicle but had no other 
lasting behavioural or physiological effects in males or females. Thus, a single dose of 1 mg/kg 
THC was deleterious with respect to motor function in otherwise healthy male rats; but this single 
1 mg/kg THC dose was otherwise benign in otherwise healthy female rats and male and female 
TBI rats. Therefore, we can conclude that (1) consequences of both TBI and THC treatment are 
sex-dependent in rats; and (2) in an animal model of mTBI, THC did not overtly change mTBI 
recovery according to the behaviour measures used in this study. These mixed effects validate the 
importance of studying sex as a biological variable of pathophysiological and pharmacological 
responses.  
 
Ongoing investigations of CNS cytokine, endocannabinoid, and CB1R and CB2R concentration 
are required to further elucidate modulatory effects and sex differences. The lack of 
pharmacological treatment and impaired quality of life associated with TBIs makes the continued 
investigations of the endocannabinoid system and the role it plays in the modulation of secondary 
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A.1. Heart rate and blood oxygen levels of 1 mg/kg THC experiment Heart rate (A, B) and 
blood oxygen levels (C,D) for male and female rats treated with 1 mg/kg THC i.p. Data are grouped 
as pre- and post-TBI or Sham-TBI.  Data are presented as mean ± S.E.M. with symbols for 
































































































































































A.2. Heart rate and blood oxygen levels of 1 mg/kg THC experiment. Heart rate (A) and blood 
oxygen levels (B) for male and female rats (combined) treated with 10 mg/kg THC i.p. Data are 
grouped as pre- and post-TBI.  Data are presented as mean ± S.E.M. with symbols for individual 

































A.3. Heart rate and blood oxygen levels of pilot experiment. Heart rate (A, B) and blood oxygen 
levels (C, D) for male and female rats in the pilot group experiment. Data are grouped as pre- and 
post-TBI.  Data are presented as mean ± S.E.M. with symbols for individual observations n=6 per 













































































A.4. Recorded weights of male and female rats at the time of injury. (A) Represents weight in 
grams of male and female rats from the 1 mg/kg experiment. (B) Represents weight in grams of 
combined male and female rats from the 10 mg/kg experiment.   
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